Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2023-09-22 Director's Dealing
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-09-22 English
Director's Dealing 2023
Director's Dealing
2023-09-22 English
Director's Dealing 2023
Director's Dealing
2023-09-22 English
Director's Dealing 2023
Director's Dealing
2023-09-22 English
Regulatory Filings 2023
Regulatory Filings
2023-08-28 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares by selling securityholders. It includes detailed information about the securities offered, the selling securityholders, risk factors, use of proceeds, and plan of distribution. The document is a registration statement prospectus, not a financial report, earnings release, or management discussion. It is a disclosure document related to capital markets and securities offerings, specifically a prospectus for resale of shares by selling securityholders. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and securities offerings. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual prospectus document. Therefore, the correct classification is CAP with high confidence.
2023-08-25 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.